跳至主要内容
临床试验/JPRN-UMIN000022185
JPRN-UMIN000022185已完成未知

Analysis on response to darbepoetin alfa in patients with low risk myelodysplastic syndromes - Myelodysplastic syndrome 01 study in West Japan Hematology Study Group (W-JHS MDS01 study)

Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu0 个研究点目标入组 85 人开始时间: 2016年5月9日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
85

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients at risk of thromboembolism with present or past medical history of myocardial infarction, pulmonary infarction and cerebral infarction or similar disorders. 2) Patients with uncontrollable hypertension. 3) Patients with medical history of drug hypersensitivity to darbepoetin alfa or other erythropoietin formulation. 4) Patients with severe (need for hospital care, or judgement by investigators) or uncontrollable complication. 5) Patients inappropriate for study participation due to complication of mental disease or psychiatric symptom. 6) Patients with cognitive disorder. 7) Patients judged by investigators to be inappropriate for study participation.

研究者

发起方
Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu

相似试验